Literature DB >> 25906117

p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature.

Andrea Remo1, Massimo Pancione, Caterina Zanella, Erminia Manfrin.   

Abstract

BACKGROUND: Prostatic specimens occasionally may contain proliferative foci of the small atypical acini that display some but not all features of prostate carcinoma. p504s is the only prostatic cancer (PC)-specific marker that, in combination with basal cell markers, help in the diagnosis of malignant lesions. Very little is known about the diagnostic importance of p16 in primary prostate carcinoma and nonmalignant elements.
MATERIALS AND METHODS: We recruited 137 of routinely diagnostic prostatic specimens (between 2009 and 2013), which consisted of 21 prostatectomy, 15 transurethral prostatic resection, and 101 needle biopsy. We evaluated p16, in comparison with p504s, in prostatic carcinoma and benign glands. In this study, both nuclear and cytoplasmatic p16 expression were considered positive.
RESULTS: We observed p16 expression in 86% of PC specimens and 16% of benign elements (P=0.001). Interestingly, p16 alone retained a high diagnostic potential in prostatectomy (95%) and in needle biopsy (84%), exhibiting a close association with PC. p504s had a high sensitivity (97%) and predictive negative value (98%) but a low specificity (71%) and predictive positive value (63%). In contrast, p16-positive expression showed a higher specificity (84%) and predictive positive value (74%) than p504s. Two prostatic carcinoma negative for p504s were positive for p16, whereas 7 cases negative for p16 were positive for p504s, and notably none was negative for both markers. In prostatectomy, p16 showed a higher diagnostic accuracy but not on transurethral prostatic resection. In needle biopsies, both markers were complementary, indicating that their combined detection may help in performing an accurate diagnosis.In conclusion, our data suggest that p16 expression is significantly enhanced in prostate carcinoma as compared with nonmalignant elements. Our results provide evidence that p16 and p504s together could improve the diagnosis of PC in prostatectomy and needle biopsies.

Entities:  

Mesh:

Year:  2016        PMID: 25906117     DOI: 10.1097/PAI.0000000000000171

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

1.  Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.

Authors:  Müjdat Yildirim; Jens Müller von der Grün; Ria Winkelmann; Emmanouil Fokas; Franz Rödel; Hanns Ackermann; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2017-01-31       Impact factor: 3.621

2.  The FENDRR/miR-214-3P/TET2 axis affects cell malignant activity via RASSF1A methylation in gastric cancer.

Authors:  Zhaocai He; Xin Wang; Changhao Huang; Yu Gao; Chen Yang; Pengwei Zeng; Zihua Chen
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

3.  Diagnostic Usefulness of p16 Immunohistochemistry for some Epithelial Lesions in the Pathology Service of Sultan Qaboos University Hospital.

Authors:  Iman Al-Ghafri; Samia Al-Husseini; Afrah Al-Rashdi; Mohammad Arafa
Journal:  Maedica (Bucur)       Date:  2021-12

4.  Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.

Authors:  Jennifer S Myers; Ariana K von Lersner; Charles J Robbins; Qing-Xiang Amy Sang
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

Review 5.  Evaluation of the use of therapeutic peptides for cancer treatment.

Authors:  Susan Marqus; Elena Pirogova; Terrence J Piva
Journal:  J Biomed Sci       Date:  2017-03-21       Impact factor: 8.410

6.  CSN6 promotes tumorigenesis of gastric cancer by ubiquitin-independent proteasomal degradation of p16INK4a.

Authors:  Wenqi Du; Zongxiang Liu; Wentao Zhu; Tongtong Li; Zhiman Zhu; Lulu Wei; Jun Song; Dongsheng Pei
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

7.  Comparative analysis of p16 expression among African American and European American prostate cancer patients.

Authors:  Myra Wong; Yaeli Bierman; Curtis Pettaway; Rick Kittles; Martha Mims; Jeffrey Jones; Michael Ittmann
Journal:  Prostate       Date:  2019-05-21       Impact factor: 4.104

8.  The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations.

Authors:  Nicola Fusco; Elena Guerini-Rocco; Alessandro Del Gobbo; Renato Franco; Federica Zito-Marino; Valentina Vaira; Gaetano Bulfamante; Giulia Ercoli; Mario Nosotti; Alessandro Palleschi; Silvano Bosari; Stefano Ferrero
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.